Robin Swartz Sells 6,500 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the sale, the chief operating officer now owns 112,328 shares of the company’s stock, valued at $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Voyager Therapeutics Trading Down 2.9 %

Shares of NASDAQ:VYGR opened at $5.74 on Friday. Voyager Therapeutics, Inc. has a 12-month low of $5.19 and a 12-month high of $11.72. The company has a market cap of $313.55 million, a PE ratio of 8.08 and a beta of 0.90. The stock has a 50 day moving average of $6.35 and a 200 day moving average of $7.01.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The firm had revenue of $24.63 million during the quarter, compared to analysts’ expectations of $12.63 million. During the same period in the prior year, the company posted ($0.59) earnings per share. Equities research analysts predict that Voyager Therapeutics, Inc. will post -0.89 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on VYGR. StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Leerink Partnrs raised Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Leerink Partners initiated coverage on Voyager Therapeutics in a research note on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price target for the company. Finally, Wedbush assumed coverage on shares of Voyager Therapeutics in a research note on Friday, November 29th. They issued an “outperform” rating and a $11.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $17.00.

Hedge Funds Weigh In On Voyager Therapeutics

Several large investors have recently made changes to their positions in VYGR. China Universal Asset Management Co. Ltd. boosted its stake in Voyager Therapeutics by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock worth $61,000 after purchasing an additional 4,098 shares during the period. Intech Investment Management LLC purchased a new position in shares of Voyager Therapeutics in the third quarter worth $74,000. SG Americas Securities LLC bought a new position in shares of Voyager Therapeutics during the second quarter worth $85,000. Victory Capital Management Inc. grew its stake in Voyager Therapeutics by 14.5% during the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after acquiring an additional 1,630 shares in the last quarter. Finally, Hsbc Holdings PLC bought a new stake in Voyager Therapeutics in the 2nd quarter valued at $128,000. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.